GLP

Business

AstraZeneca Bets $18.5 Billion on CSPC's Monthly Obesity Shot in Major Pipeline Push

In a landmark deal, AstraZeneca has licensed a suite of next-generation weight-loss drugs from China's CSPC, aiming to challenge the dominance of Lilly and Novo Nordisk with longer-acting monthly injectables.

Business

Eli Lilly's Q4 Earnings Loom: A Buying Opportunity or a Gamble?

As Eli Lilly prepares to report its Q4 and full-year 2025 results on February 4th, investors are weighing whether the pharmaceutical giant's premium valuation leaves room for a positive surprise, or if the stock is priced for perfection.

Business

Fast-Casual Dining Stocks Stage a Surprising Rebound Amid Shifting Consumer Habits

After a brutal 2025, fast-casual restaurant stocks are rallying sharply in early 2026. Analysts debate whether this marks a genuine recovery or a temporary bounce, as consumers pivot towards grocery and convenience store meals, forcing a reckoning on value and quality.